| Code | CSB-RA008545MB6HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to VRDN-006, designed to target the neonatal Fc receptor (FCGRT), a critical immunoglobulin transport protein. FCGRT plays an essential role in maintaining serum IgG homeostasis by rescuing antibodies from lysosomal degradation and extending their half-life in circulation. This receptor also mediates bidirectional IgG transport across epithelial barriers and facilitates immune complex clearance. Dysregulation of FCGRT function is implicated in various autoimmune disorders, including myasthenia gravis, immune thrombocytopenia, and pemphigus, where pathogenic autoantibodies contribute to disease pathology.
VRDN-006 represents a therapeutic approach targeting the FCGRT pathway to reduce pathogenic IgG levels in autoimmune conditions. This biosimilar antibody provides researchers with a valuable tool for investigating FCGRT biology, antibody recycling mechanisms, and IgG-mediated immune responses. It supports studies examining therapeutic strategies for autoimmune diseases and enables exploration of antibody pharmacokinetics and immune regulation in various experimental models.
There are currently no reviews for this product.